Navigating Humana Evrysdi Prior Authorization for Spinal Muscular Atrophy

Streamlining the **Humana Evrysdi prior authorization** process is critical for ensuring timely access to this essential therapy for patients with Spinal Muscular Atrophy (SMA).

Prior authorization for high-cost, specialty medications like Evrysdi presents significant administrative burdens for revenue cycle and prior authorization teams. Understanding Humana's specific requirements, submission channels, and policy nuances is key to minimizing delays, reducing denials, and optimizing patient care pathways. Klivira provides the automation and intelligence to navigate these complexities efficiently.

Evrysdi and Humana Coverage Dynamics

Evrysdi (risdiplam) is a critical SMN2 splicing modifier indicated for the treatment of Spinal Muscular Atrophy (SMA) in pediatric and adult patients. As a high-cost specialty medication, it consistently requires prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans. Humana, a leading Medicare Advantage carrier, applies specific utilization management criteria to ensure appropriate use of Evrysdi within its covered populations.

Key Humana Prior Authorization Submission Channels for Evrysdi

**Medical Benefit (e.g., Physician-administered):** Initiate prior authorization for Evrysdi via the Availity Essentials portal, which surfaces Humana's dedicated PA tool and document upload capabilities. X12 278 transactions are also supported through clearinghouses.
**Pharmacy Benefit (e.g., Self-administered):** For Evrysdi dispensed under the pharmacy benefit, submissions route through Humana's pharmacy benefit operation. Prescriber-initiated ePA workflows are supported via CoverMyMeds and Surescripts.
**Specialty Pharmacy:** CenterWell Specialty Pharmacy handles complex medications like Evrysdi on the pharmacy benefit. Medical-benefit specialty drugs follow Humana's standard medical PA channel, often with site-of-care policies.

Utilization Management Policies and Criteria

Humana publishes specific medical policies and coverage determinations for Evrysdi on its provider site, outlining medical necessity criteria. For Medicare Advantage members, these policies must align with applicable CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs), ensuring that criteria are not more restrictive than Original Medicare. Criteria sources may include Humana-developed guidelines or third-party references like MCG.

Common Denial Reasons and Humana Appeal Pathways for Evrysdi

**Medical Necessity/Insufficient Documentation:** Lack of comprehensive clinical evidence supporting diagnosis, previous treatments, or patient-specific criteria outlined in Humana's policy.
**NCD/LCD Non-coverage (Medicare Advantage):** Failure to meet specific coverage rules for Medicare Advantage plans, which must align with Original Medicare NCDs and LCDs.
**Step Therapy Requirements:** Non-adherence to Humana's formulary-driven step therapy protocols, where other preferred treatments must be attempted or contraindications documented.
**Site-of-Service Mismatch:** Discrepancies between the requested site of care and Humana's site-of-care policies for specialty drugs.
**Appeal Process:** Humana documents its appeal pathway in the provider manual. Medicare Advantage appeals follow the CMS-mandated 5-level structure, while commercial appeals have distinct pathways. Peer-to-peer reviews and expedited appeals are available.

Turnaround Times and CMS-0057-F Impact

Humana publishes precertification turnaround commitments on its provider site. For Medicare Advantage lines, standard pre-service organization determinations historically adhere to 14 calendar days, with 72 hours for expedited requests. The CMS-0057-F rule impacts Humana's Medicare Advantage operations, tightening standard PA decision timeframes to 7 calendar days and expedited to 72 hours for specific impacted transaction categories, with phased compliance through 2027.

Electronic Prior Authorization (ePA) Capabilities

Humana actively participates in the HL7 Da Vinci Project ecosystem, indicating a commitment to advancing electronic prior authorization (ePA) capabilities, including Da Vinci PAS. For pharmacy benefit Evrysdi, ePA is supported through platforms like CoverMyMeds and Surescripts. Medical-benefit ePA often leverages X12 278 transactions, which Klivira integrates directly to streamline submissions.

Frequently asked questions

How do I submit a prior authorization for Evrysdi to Humana?

Prior authorization for medical benefit Evrysdi can be submitted via the Availity Essentials portal or through X12 278 transactions. For pharmacy benefit Evrysdi, submissions typically route through Humana's pharmacy benefit operation, with ePA supported by platforms like CoverMyMeds and Surescripts.

What are common reasons Humana denies Evrysdi prior authorizations?

Common denial reasons include insufficient documentation to meet medical necessity criteria, failure to adhere to step therapy requirements, non-alignment with NCDs/LCDs for Medicare Advantage plans, or discrepancies in the requested site of service. Review Humana's specific medical policy for detailed criteria.

What are the typical turnaround times for Evrysdi prior authorization with Humana?

For Medicare Advantage, standard pre-service organization determinations are typically 14 calendar days, with expedited requests at 72 hours. Under the CMS-0057-F rule, standard PA decision timeframes for impacted categories will tighten to 7 calendar days, while expedited remains 72 hours.

Does Humana require step therapy for Evrysdi?

As a high-cost specialty medication, Evrysdi may be subject to Humana's formulary-driven step therapy protocols. It is essential to consult the specific Humana medical policy or formulary for Evrysdi to understand any prerequisite therapies or quantity limits.

How does CMS-0057-F affect Evrysdi prior authorizations with Humana?

Humana's Medicare Advantage lines are squarely in scope for CMS-0057-F. This means tighter standard PA decision timeframes (7 days) for impacted transactions and a requirement for electronic PA API conformance by 2027, which will impact how Evrysdi PAs are processed.